Company: TELO
Filing Date: 2025-11-20
Form Type: PREM14A
Source: 0001493152-25-024463
Chunk: 95

Company: Telomir Pharmaceuticals, Inc.
Filing Date: 2025-11-20
Form: PREM14A
Chunk 95
---
 to protect, our technology in the event of unauthorized use or disclosure of information. Furthermore, our trade secrets may otherwise become known to, or be independently developed by, our competitors. We intend to seek appropriate patent protection for technology in our research and development programs, where applicable, and their uses by filing patent applications in the United States and other selected countries. We intend for these patent applications to cover, where possible, claims for compositions of matter, medical uses, processes for preparation and formulations.

Properties

Our current business address 3014 West Palmira Ave., Suite 302, Tampa, FL 33629.

Employees

As of November 2025, we have no full-time employee and various consultants providing support.

Legal Proceedings

From time to time, we may be named in claims arising in the ordinary course of business. Currently, no legal proceedings, government actions, administrative actions, investigations, or claims are pending against us or involve us that, in the opinion of our management, could reasonably be expected to have a material adverse effect on our business and financial condition.

We anticipate that we will expend significant financial and managerial resources in the defense of our intellectual property rights in the future if we believe that our rights have been violated. We also anticipate that we will expend significant financial and managerial resources to defend against claims that our products and services infringe upon the intellectual property rights of third parties.

<div align='center'>MATTERS BEING SUBMITTED TO A VOTE OF TELO’S STOCKHOLDERS

PROPOSAL NO. 1:

APPROVAL OF THE ISSUANCE OF SHARES OF TELO COMMON STOCK OR OTHER SECURITIES OF TELO PURSUANT TO THE MERGER, WHICH WILL REPRESENT (OR ARE CONVERTIBLE INTO) MORE THAN 20% OF THE SHARES OF TELO COMMON STOCK OUTSTANDING IMMEDIATELY PRIOR TO THE MERGER PURSUANT TO NASDAQ LISTING RULE 5635(A)</div>

At the TELO Annual Meeting, TELO’s stockholders will be asked to approve the issuance of shares of TELO Common Stock or other securities of TELO to the holders of TELI Capital Stock and warrants to purchase TELI Capital Stock pursuant to the Merger, which shares of TELO Common Stock or other securities of TELO will represent (or are convertible into) more than 20% of the shares of TELO Common Stock outstanding immediately prior to the Merger, pursuant to Nasdaq Listing Rule 5635(a).

| 54 |

Immediately after the Merger